A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma

• Status: COMPLETED
• Trial end date: 2024-01-03

Summary

This study was an open, single-arm, enriched, multicenter Phase II study.

• Phase: PHASE2

Details

• Lead Sponsor: Shandong New Time Pharmaceutical Co., LTD